Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Beijing Tide Pharmaceuticaql Co. Ltd. currently holds 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio's activity is limited to 1 distinct examiner and a single distinct art unit, indicating a very specific area of current patent interest. This concentration is typical for companies focusing on a niche biotechnological process during this phase of prosecution.
The busiest examiner, RAO, SAVITHA M, is handling the pending action. Since there is only the 1 pending office action for the entire company, the prosecution strategy is currently focused on a single application, requiring a targeted approach to satisfy the requirements of the assigned art unit. Practitioners should be aware that the outcome of this matter will be the sole determinant of the company's near-term success in the Biotechnology & Pharmaceuticals sector, as no other examiners are currently involved in their pending workload.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, SAVITHA M | 1 | 60.7% | +29.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18427932 | SHP2 INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND APPLICATION THEREOF | RAO, SAVITHA M | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18427932 | SHP2 INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND APPLICATION THEREOF | RAO, SAVITHA M | 1691 | §112DP | Non-Final OA | — | Pending | Jan 31, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeijing Tide Pharmaceuticaql Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Savitha M Rao has the most, with 1 of Beijing Tide Pharmaceuticaql Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
